1. Home
  2. NVRO vs RVMDW Comparison

NVRO vs RVMDW Comparison

Compare NVRO & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVRO
  • RVMDW
  • Stock Information
  • Founded
  • NVRO 2006
  • RVMDW N/A
  • Country
  • NVRO United States
  • RVMDW United States
  • Employees
  • NVRO N/A
  • RVMDW 443
  • Industry
  • NVRO Medical/Dental Instruments
  • RVMDW
  • Sector
  • NVRO Health Care
  • RVMDW
  • Exchange
  • NVRO Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • NVRO N/A
  • RVMDW N/A
  • IPO Year
  • NVRO 2014
  • RVMDW N/A
  • Fundamental
  • Price
  • NVRO $4.45
  • RVMDW $0.55
  • Analyst Decision
  • NVRO Hold
  • RVMDW
  • Analyst Count
  • NVRO 14
  • RVMDW 0
  • Target Price
  • NVRO $9.00
  • RVMDW N/A
  • AVG Volume (30 Days)
  • NVRO 573.4K
  • RVMDW N/A
  • Earning Date
  • NVRO 11-11-2024
  • RVMDW N/A
  • Dividend Yield
  • NVRO N/A
  • RVMDW N/A
  • EPS Growth
  • NVRO N/A
  • RVMDW N/A
  • EPS
  • NVRO N/A
  • RVMDW N/A
  • Revenue
  • NVRO $419,146,000.00
  • RVMDW N/A
  • Revenue This Year
  • NVRO N/A
  • RVMDW N/A
  • Revenue Next Year
  • NVRO $2.50
  • RVMDW N/A
  • P/E Ratio
  • NVRO N/A
  • RVMDW N/A
  • Revenue Growth
  • NVRO N/A
  • RVMDW N/A
  • 52 Week Low
  • NVRO $4.38
  • RVMDW N/A
  • 52 Week High
  • NVRO $22.64
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • NVRO 37.89
  • RVMDW N/A
  • Support Level
  • NVRO $4.82
  • RVMDW N/A
  • Resistance Level
  • NVRO $6.85
  • RVMDW N/A
  • Average True Range (ATR)
  • NVRO 0.53
  • RVMDW 0.00
  • MACD
  • NVRO -0.05
  • RVMDW 0.00
  • Stochastic Oscillator
  • NVRO 0.41
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: